Treatments

New MIT center to fund autism research

Source: 
The Boston Globe
Date Published: 
December 15, 2011
Abstract: 

A new center at the Massachusetts Institute of Technology will focus on unraveling the neuroscience behind social behaviors, helping to push forward research and, the scientists hope, to advance diagnosis and treatment of autism spectrum disorders.

Repetitive behaviors in adults with Autism Spectrum disorders significantly lessen with antidepressant treatment

Source: 
MedicalXpress
Date Published: 
December 5, 2011
Abstract: 

Restricted, repetitive behavior, such as compulsive arranging and rigid adherence to routines, is a defining symptom of autism spectrum disorders. A 12-week study showed that the antidepressant fluoxetine produced a greater decrease in repetitive behaviors and more overall improvement than placebo in adults with autism spectrum disorders.

Structure of language pathways differs in non-verbal autism

Source: 
SFARI
Date Published: 
November 14, 2011
Abstract: 

Non-verbal children with autism show structural differences in key language areas of the brain compared with controls, according to a poster presented Saturday at the Society for Neuroscience annual meeting in Washington, D.C.

Study In Fruit Flies Has Implications For Autism, Other Cognitive Impairment Syndromes

Source: 
Medical News Today
Date Published: 
November 1, 2011
Abstract: 

Loss of FMR1 function is the most common genetic cause of autism. Understanding how this gene works is vital to finding new treatments to help Fragile X patients and others...

Institute For Basic Research in New York seeking adults with Fragile X for New Clinical Trial

Source: 
October 17, 2011
Abstract: 

The Institute for Basic Research in Staten Island is seeking adult participants for a new Fragile X treatment trial. This is a large scale trial of AFQ056 from Novartis for people aged 18-45 who have Fragile X. AFQ056 is an mGluR5 antagonist. The current study is just for adults but the next step is to extend the trial to ages 12-17. After completing the 20 week trial, participants will be offered the option of taking this medication free of charge until it comes to market.

The Institute for Basic Research in Staten Island is seeking adult participants for a new Fragile X treatment trial. 

This is a large scale trial of AFQ056 from Novartis for people aged 18-45 who have Fragile X.  AFQ056 is an mGluR5 antagonist.  The current study is just for adults but the next step is to extend the trial to ages 12-17.  After completing the 20 week trial, participants will be offered the option of taking this medication free of charge until it comes to market.

The principal investigator on this study is Dr. Angelo Porto, Dept. of Psychology, Institute for Basic Research(IBR). porto_a@medscape.com or 718-494-8028

Additional information about AFQ056 and the study can be found at fraxa.org/getInvolved_studies.aspx

Illinois medical board files complaint against star autism doctor

Source: 
Chicago Tribune
Date Published: 
October 14, 2011
Abstract: 

Dr. Anjum Usman, of Naperville, has been a star in the world of alternative treatments for autism for years, but now she's facing professional discipline for her approach to the frustrating disorder.

According to the complaint, which was filed Wednesday, Usman "made statements to (the boy's) mother that the prescribed treatments had positive clinical benefits for children with autism, despite the lack of empirical research."

Philadelphia becomes hotbed of autism research

Source: 
Philadelphia Inquirer
Date Published: 
October 9, 2011
Abstract: 

Five years ago, Philadelphia was not on the map when it came to researching one of the most mysterious and expensive childhood medical conditions of our time. Now it is among the top cities in the nation, with expertise in nearly all the key fields - genetics, environmental exposure, brain imaging, behavioral interventions - that are critical for finding causes and developing treatments. Most of the local talent is at the Center for Autism Research at Children's Hospital, which in less than four years has grown into a powerhouse with more than 100 researchers and staff running two dozen studies.

'Autistic' mice created – and treated

Source: 
New Scientist
Date Published: 
October 3, 2011
Abstract: 

A new strain of mice engineered to lack a gene with links to autism displays many of the hallmarks of the condition. It also responds to a drug in the same way as people with autism, which might open the way to new therapies for such people.

Children With Autism Benefit from Early, Intensive Therapy

Source: 
Science Daily
Date Published: 
September 28, 2011
Abstract: 

A primary characteristic of autism spectrum disorders (ASD) is impairments in social-communication skills. Children and adolescents with social-communication problems face difficulty understanding, interacting and relating with others. University of Missouri researchers found that children who receive more intensive therapy to combat these impairments, especially at early ages, achieve the best outcomes.

Animal Model Research Could Lead To The Development Of Diagnostic Tests For Autism Based On Biomarkers

Source: 
Medical News Today
Date Published: 
September 14, 2011
Abstract: 

The first transgenic mouse model of a rare and severe type of autism called Timothy Syndrome is improving the scientific understanding of autism spectrum disorder in general and may help researchers design more targeted interventions and treatments.